Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Hyaluronic Acid Vaginal Suppository (Revaree Plus) to Improve Vaginal Health in Women Receiving Aromatase Inhibitor or Tamoxifen for Stage 0-3 Hormone Receptor Positive Breast Cancer

Trial Status: active

This phase IV trial tests how well giving a hyaluronic acid vaginal suppository (Revaree Plus) works to improve vaginal health in women receiving an aromatase inhibitor or tamoxifen for stage 0-3 hormone receptor positive breast cancer. Breast cancer treatments can have significant impacts on vulvovaginal health and sexual wellbeing, either by inducing menopause or worsening menopausal symptoms. Non-hormonal vaginal suppositories containing hyaluronic acid work by increasing hydration of the vaginal tissue and therefore exerting a moisturizing effect on the skin. Ravaree Plus may be effective in improving vaginal health in women receiving an aromatase inhibitor or tamoxifen for stage 0-3 hormone receptor positive breast cancer.